Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD): post hoc analyses of the EMPA-REG OUTCOME trial

被引：0
|
作者：
Ferreira, J. P. [1 ]
Verma, S. [2 ]
David, F. [3 ]
Ofstad, A. P. [4 ]
Lauer, S. [5 ]
Zwiener, I. [5 ]
George, J. T. [6 ]
Wanner, C. [7 ]
Zinman, B. [8 ]
Inzucchi, S. E. [9 ]
机构：
[1] Univ Lorraine, Inserm 1433, Ctr Invest Clin Plurithemat, Nancy, France
[2] Univ Toronto, Div Cardiac Surg, St Michaels Hosp, Toronto, ON, Canada
[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[4] Boehringer Ingelheim Norway KS, Asker, Norway
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[7] Wurzburg Univ Clin, Wurzburg, Germany
[8] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[9] Yale Univ, Sch Med, New Haven, CT USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
947
引用
收藏
页码：S450 / S451
页数：2
相关论文
共 50 条
  • [11] External Applicability of REDUCE-IT in a Large Diabetes Cardiovascular Outcomes Trial: A Post Hoc Analysis of EMPA-REG OUTCOME
    Verma, Subodh
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Fitchett, David H.
    Ofstad, Anne Pernille
    Wanner, Christoph
    George, Jyothis T.
    Mattheus, Michaela
    Zinman, Bernard
    Lawler, Patrick R.
    CIRCULATION, 2020, 142
  • [12] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffery
    Ofstad, Anne Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina
    INTERNIST, 2022, 63 (SUPPL 3): : 316 - 316
  • [13] Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial
    Vaduganathan, Muthiah
    Inzucchi, Silvio E.
    Sattar, Naveed
    Fitchett, David H.
    Ofstad, Anne Pernille
    Brueckmann, Martina
    George, Jyothis T.
    Verma, Subodh
    Mattheus, Michaela
    Wanner, Christoph
    Zinman, Bernard
    Butler, Javed
    DIABETES OBESITY & METABOLISM, 2021, 23 (12): : 2775 - 2784
  • [14] Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
    Ferreira, Joao Pedro
    Fitchett, David
    Ofstad, Anne Pernille
    Kraus, Bettina Johanna
    Wanner, Christoph
    Zwiener, Isabella
    Zinman, Bernard
    Lauer, Sabine
    George, Jyothis T.
    Rossignol, Patrick
    Zannad, Faiez
    AMERICAN JOURNAL OF HYPERTENSION, 2020, 33 (12) : 1092 - 1101
  • [15] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, A.
    Inzucchi, S. E.
    Testani, J.
    Ofstad, A. P.
    Fitchett, D.
    Mattheus, M.
    Verma, S.
    Zannad, F.
    Wanner, C.
    Kraus, B. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 175 - 175
  • [16] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
    Verma, Subodh
    Mazer, C. David
    Bhatt, Deepak L.
    Raj, Satish R.
    Yan, Andrew T.
    Verma, Atul
    Ferrannini, Ele
    Simons, Gudrun
    Lee, Jisoo
    Zinman, Bernard
    George, Jyothis T.
    Fitchett, David
    DIABETES CARE, 2019, 42 (03) : E42 - E44
  • [17] Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria
    Verma, Subodh
    Kosmopoulos, Andrew
    Bhatt, Deepak L.
    Fitchett, David
    Ofstad, Anne Pernille
    Wanner, Christoph
    Mattheus, Michaela
    Zinman, Bernard
    Lawler, Patrick R.
    Leiter, Lawrence A.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 15
  • [18] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
    Kaku, Kohei
    Lee, Jisoo
    Mattheus, Michaela
    Kaspers, Stefan
    George, Jyothis
    Woerle, Hans-Juergen
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    Lamkanfi, F.
    CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
  • [19] Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
    Waijer, Simke W.
    Xie, Di
    Inzucchi, Silvio E.
    Zinman, Bernard
    Koitka-Weber, Audrey
    Mattheus, Michaela
    von Eynatten, Maximillian
    Inker, Lesley A.
    Wanner, Christoph
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (18):
  • [20] Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
    Odutayo, Ayodele
    Zinman, Bernard
    Wanner, Christoph
    Zwiener, Isabella
    Lund, Soren S.
    Hantel, Stefan
    Fitchett, David
    Udell, Jacob A.
    CJC OPEN, 2024, 6 (07) : 868 - 875
12345